Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
Arbutus Biopharma Corp (ABUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 , in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tolerated and appears to result in continued HBsAg declines in some patients First patient dosed in additional arm of Phase 2a clinical trial combining imdusiran, VTP-300, NA therapy and nivolumab – advancing towards goal of further stimulating host HBV-associated immunity Cash runway into the first quarter of 2025 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 03, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutica...",
"Corporate Presentation"
03/02/2023 8-K Quarterly results
Docs: "Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase 1 clinical trial for oral M pro coronavirus candidate, AB-343, expected in the second half of 2023 Strengthened financial position – cash runway into Q4 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., March 02, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific vi...",
"Corporate Presentation"
11/09/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update Key milestones across our chronic hepatitis B virus and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates. “This quarter we presented data at the EASL ILC which highlighted the advancements we have made in developing our lead RNAi therapeutic AB-729, capsid inhibitor AB-836, and PD-L1 inhi..."
05/05/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021 First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleoside analog therapy On-track to initiate several proof-of-concept Phase 2a clinical trials with AB-729 as a cornerstone agent in combination with other approved or investigational compounds Commenced IND enabling studies for Arbutus’ oral PD-L1 program Cash runway guidance extended into the second quarter of 2023 Conference call and webcast scheduled today at 8:45 AM ET WARMINSTER, Pa., Nov. 04, 2021 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad po...",
"Corporate Presentation"
08/05/2021 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update New data on AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™; all AB-729 abstracts selected for best of ILC™ Announced two additional proof-of-concept clinical collaborations to evaluate AB-729 in combination with agents from Vaccitech plc and Antios Therapeutics, Inc. Announced U.S. Food and Drug Administration authorization to proceed with an Investigational New Drug application in a Phase 2a clinical trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleoside analog therapy and short courses of Peg-IFNα-2a in subjects with chronic HBV Presentation at EASL of pre-clini...",
"Corporate Presentation dated August 2021"
03/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus infection, to be presented at the upcoming American Association for the Study of Liver Disease Conference Clinical collaboration with Assembly Biosciences, Inc. established to evaluate Arbutus’ AB-729 in combination with vebicorvir, Assembly’s oral core/capsid inhibitor AB-836, Arbutus’ oral capsid inhibitor, remains on track for completion of CTA/IND-enabling studies by the end of 2020 Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Nov. 05, 2020 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company primarily f..."
08/07/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/05/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
05/06/2019 8-K Quarterly results
Docs: "Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update"
11/07/2018 8-K Quarterly results
Docs: "Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update"
11/03/2016 8-K Quarterly results
Docs: "Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results"
08/04/2016 8-K Quarterly results
Docs: "Arbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results"
05/04/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Arbutus Biopharma Announces Third Quarter 2015 Financial Results"
08/05/2015 8-K Quarterly results
Docs: "Arbutus Biopharma Announces Second Quarter 2015 Financial Results"
05/06/2015 8-K Quarterly results
Docs: "Tekmira Provides Corporate Update and Announces First Quarter 2015 Results Conference Call at 4:30 pm Eastern Time Today"
11/06/2014 8-K Quarterly results
Docs: "Tekmira Provides Corporate Update and Announces Third Quarter 2014 Results Conference Call at 5:00 pm Eastern Time Today"
05/14/2014 8-K Quarterly results
Docs: "Tekmira Provides Corporate Update and Announces First Quarter 2014 Results Conference Call at 4:30 pm Eastern Time Today"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy